Chelation Nanoparticles for Vascular Senescence Without Apoptosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing senolytic therapies that induce apoptosis in senescent cells can lead to adverse effects such as hemorrhage and strain on blood filtration systems, and there is a need for a therapy that reduces the negative effects of senescent cells without causing apoptosis.

Innovation Solution

Administration of nanoparticles comprising a chelating agent, such as EDTA, to sequester metals and reduce extracellular calcium deposits, thereby decreasing the expression of the NLRP3 inflammasome and senescence-associated secretory phenotype (SASP), using a carrier like liposomes or polymeric particles to target specific tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If senolytic therapies induce apoptosis in senescent cells, then the number of senescent cells is reduced, but hemorrhage and strain on blood filtration systems occur

Engineering Contradiction:

Improvenumber of senescent cellsVSAvoidhemorrhage and strain on blood filtration systems

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

Instead of inducing apoptosis to eliminate senescent cells, the patent uses chelating agents to reverse the senescent state by sequestering extracellular calcium and metal ions, thereby converting the harmful effect into a beneficial therapeutic approach that reduces senescent cell accumulation without causing cell death

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent introduces chelating agents as intermediary substances that mediate between the senescent cells and the harmful effects. These agents bind to extracellular calcium and metal ions, interrupting the pathological processes without directly killing the cells, thus avoiding hemorrhage and blood filtration strain

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If senescent cells are eliminated through apoptosis, then age-related diseases are treated, but off-target side effects occur

Engineering Contradiction:

Improvetreatment of age-related diseasesVSAvoidoff-target side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies chelating agents locally to specific tissues affected by senescence, such as vascular tissues and kidneys, rather than systemically inducing apoptosis. This localized approach treats age-related diseases while minimizing off-target effects on other organs and cell types

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the therapeutic parameter from cell death induction to extracellular calcium and metal ion sequestration. By altering the biochemical environment through chelation, the therapy treats age-related diseases with improved safety and reduced off-target side effects

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Reduces senescent cell accumulation and SASP without inducing apoptosis, thereby mitigating age-related diseases and vascular calcification while minimizing off-target side effects.

Implementation Method 1

Administration of nanoparticles comprising a chelating agent, such as EDTA, to sequester metals and reduce extracellular calcium deposits

Methodology Applied

Scientific EffectChelation:

Implementation Method 2

using a carrier like liposomes or polymeric particles to target specific tissues

Methodology Applied

Scientific EffectNanoparticle delivery:

Data Source

PatentUS20260021066A1Chelation Therapy to Limit Cell Senescence

Publication Date: 2026.01.22 CLEMSON UNIVERSITY

AI summary

The present application is generally directed to methods for chelating calcium deposits within calcified blood vessels, as well as methods and compositions for use in regulating various senescence-related inflammatory pathways.